Author

M. D. Hellmann

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3 Immunology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 5 Approach:statistical model· 4 Research Focus:cell type annotation· 3 Research Focus:differential expression· 3 Assay:bulk RNA-seq· 2 Research Focus:drug response / drug discovery· 2 Assay:scRNA-seq· 2 Research Focus:cell-cell communication· 1

Frequent Co-Authors

T. Merghoub· 5 shared A. Chow· 3 shared H. Rizvi· 3 shared A. J. Plodkowski· 2 shared A. Quintanal-Villalonga· 2 shared C. M. Rudin· 2 shared E. de Stanchina· 2 shared J. D. Wolchok· 2 shared

Activity by Year

2016-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

5 shared papersCancer Biology

T. Merghoub

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

CD39 Identifies Tumor-Reactive CD8 T cells in Patients With Lung Cancer

A. Chow, F. Z. Uddin, L. Mangarin, H. Rizvi, A. Dobrin, S. E. Tischfield, A. Quintanal-Villalonga, J. M. Chan, N. S. Shah, V. Allaj, P. Manoj, M. Mattar, M. Meneses, M. Liu, R. Landau, , C. M. Rudin

This study identifies CD39 as a marker for tumor-reactive CD8 T cells in lung cancer, showing its association with clinical outcomes and response to immune checkpoint therapy.

bioRxiv · Jan 24, 2022 · PreprintImmunology

Regional and clonal T cell dynamics at single cell resolution in immune checkpoint blockade

J. A. Pai, A. Chow, J. Sauter, M. Mattar, H. Rizvi, H. J. Woo, N. Shah, F. Uddin, A. Quintanal-Villalonga, J. M. Chan, P. Manoj, V. Allaj, M. Baine, J. E. Chaft, A. J. Plodkowski, , M. D. Hellmann

This study uses scTCR/RNA-seq to analyze T cell dynamics in lung cancer patients before and after ICB, finding regional heterogeneity and clonal persistence associated with clinical responses.

bioRxiv · Sep 27, 2021 · PreprintImmunology

Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer

D. Memon, H. Rizvi, G. Fromm, J. Lihm, A. J. Schoenfeld, J. L. Sauter, J. Luo, A. Chow, U. K. Bhanot, C. McCarthy, D. Ye, C. M. Vanderbilt, C. Liu, M. Abu-Akeel, A. J. Plodkowski, , M. D. Hellmann

This study characterizes clinical and molecular features of acquired resistance to PD-(L)1 blockade in NSCLC, identifying persistent inflammation and dysfunctional IFN signaling as key features.

bioRxiv · Jul 21, 2021Cancer Biology

Escape from nonsense mediated decay associates with anti-tumor immunogenicity

K. Litchfield, J. Reading, E. Lim, H. Xu, P. Liu, M. Al-Bakir, S. Wong, A. Rowan, S. Funt, T. Merghoub, M. Lauss, I. M. Svane, G. Jonsson, J. Herrero, J. Larkin, , C. Swanton

This study identifies NMD-escape fs-indels as a biomarker associated with improved response to immunotherapy in melanoma patients.

bioRxiv · Nov 14, 2019Cancer Biology

Somatic Mutations and Neoepitope Homology in Melanomas Treated with CTLA-4 Blockade

T. Nathanson, A. Ahuja, A. Rubinsteyn, B. A. Aksoy, M. D. Hellmann, D. Miao, E. Van Allen, T. Merghoub, J. Wolchok, A. Snyder, J. Hammerbacher

The paper reanalyzes exome and RNA-Seq data from melanoma patients treated with CTLA-4 blockade to assess the predictive value of somatic mutation burden and neoepitope homology to pathogens.

bioRxiv · Nov 17, 2016Cancer Biology